Drug intelligence / Profile preview

NX9 Oral Contrast Agent

Development stage: Phase 2
Lead developer: Nextrast
Modality: Small Molecules
Administration: Oral

Overview

NX9 Oral Contrast Agent is a novel dark borosilicate oral contrast agent developed by Nextrast, Inc. for use in CT imaging of the abdomen and pelvis. It is an inorganic mineral compound designed to improve bowel delineation—specifically marking and distention—enabling radiologists to better visualize bowel structures and detect diseases such as gastrointestinal carcinoma and inflammatory bowel disease. It is currently being evaluated in a Phase 2 clinical trial (NCT04789200) to assess its safety, pharmacokinetics, and efficacy in patients with gastrointestinal disorders.

Other names: oral bowel contrast agent NX9NX-9NX9NX 9NX9 Oral Contrast AgentNX-9 Oral Contrast AgentNX 9 Oral Contrast Agent

Beyond the preview

Go deeper on NX9 Oral Contrast Agent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NX9 Oral Contrast Agent.

Explore the full profile